S&P 500
(1.26%) 5 127.79 points
Dow Jones
(1.18%) 38 676 points
Nasdaq
(1.99%) 16 156 points
Oil
(-1.22%) $77.99
Gas
(5.65%) $2.15
Gold
(0.02%) $2 310.10
Silver
(-0.16%) $26.79
Platinum
(0.37%) $966.20
USD/EUR
(-0.35%) $0.929
USD/NOK
(-1.07%) $10.87
USD/GBP
(-0.11%) $0.797
USD/RUB
(0.35%) $91.45

实时更新: Poxel SA [POXEL.PA]

交易所: EURONEXT 工业: Biotechnology
最后更新时间3 May 2024 @ 23:35

8.22% 0.645

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 23:35):

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight...

Stats
今日成交量 574 184
平均成交量 334 305
市值 29.99M
EPS €0 ( 2024-04-08 )
下一个收益日期 ( €0 ) 2024-05-15
Last Dividend €0 ( N/A )
Next Dividend €0 ( N/A )
P/E -0.600
ATR14 €0.00400 (0.63%)

音量 相关性

長: 0.21 (neutral)
短: -0.03 (neutral)
Signal:(41.842) Neutral

Poxel SA 相关性

10 最正相关
10 最负相关

你知道吗?

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。

相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Poxel SA 相关性 - 货币/商品

The country flag 0.26
( neutral )
The country flag -0.49
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.77
( moderate )

Poxel SA 财务报表

Annual 2023
营收: €1.98M
毛利润: €1.98M (100.00 %)
EPS: €0
FY 2023
营收: €1.98M
毛利润: €1.98M (100.00 %)
EPS: €0
FY 2022
营收: €674 000
毛利润: €2 000.00 (0.30 %)
EPS: €-1.080
FY 2021
营收: €13.40M
毛利润: €13.34M (99.56 %)
EPS: €-0.830

Financial Reports:

No articles found.

Poxel SA

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). The company has a licensing agreement with Enyo Pharma S.A.S. for the development of PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist that is in Phase II study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

关于 实时信号

此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。

实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。